PHILADELPHIA, July 20 /U.S. Newswire/ -- Imaging techniques such as PET and MRI are near to becoming useful in diagnosing Alzheimer's disease earlier and distinguishing it from other types of dementia, according to research reported today at the 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD), presented by the Alzheimer's Association.
For example, one study at the conference reports the latest data on a new PET technology that allows researchers to see - for the first time - accumulations of the abnormal protein tau in the brains of people with a rare form of dementia.
"Having the ability to observe the damage and progression of Alzheimer's in the living brain will have a profound impact on how we diagnose the disease, as well as how we gauge the effectiveness of current medical treatments and those in development," said William Thies, Ph.D., vice president of Medical & Scientific Affairs for the Alzheimer's Association.
Researchers View the Early Stages of Alzheimer's In the Brain Advances in positron emission tomography (PET) allow researchers to evaluate brain changes of people whose mild cognitive impairment (MCI) may represent the early stages of Alzheimer's. William E. Klunk, M.D., Ph.D., and colleagues at the University of Pittsburgh have recently developed a compound known as Pittsburgh Compound-B (PIB) - visible on PET scans - that sticks to abnormal clumps of protein in the brain called amyloid plaques. Plaques and other abnormal protein aggregates called tangles are the hallmarks of Alzheimer's disease. The main component of the plaques, a toxic protein fragment called beta- amyloid, is a primary suspect in the death of brain cells in Alzheimer's.
Klunk and colleagues presented PET scan data from a preliminary study of five people with MCI. They found that the subjects fall into two distinct groups. One group has evidence of amyloid deposition that is indistinguishable from normal controls, and the other group has evidence of amyloid deposition that is indistinguishable from Alzheimer's disease patients.
Some people with MCI progress to Alzheimer's while others do not. It may be that levels of amyloid in the brain are related to who develops the disease. The researchers will attempt to replicate these results in a much larger study.
"Amyloid imaging with PET may become useful for predicting which people with MCI will progress to Alzheimer's in the near future. The technology might also help to determine the effectiveness of anti-amyloid therapies in people with MCI and Alzheimer's," said Klunk.
-- First Visualization of "Tangles" in Frontotemporal Dementia
Another PET development allows researchers to see-for the first time-accumulations of the abnormal protein tau in the brains of people with a rare form of dementia. Gary Small, M.D., of the University of California, Los Angeles, and his colleagues have developed a PET compound, (F-18)FDDNP, that "sticks" both to amyloid plaques and the tangles of abnormal tau protein in the brains of Alzheimer's patients. In their report at ICAD, the researchers used this new compound to map the tangles also found in frontotemporal dementia (FTD), a rare disorder with symptoms similar to Alzheimer's.
"We believe this is the first time tau accumulation has been visualized in living patients," said Small. "The new technique may help us better differentiate between Alzheimer's and other forms of dementia - leading to more effective treatments."
The researchers compared PET scans of people with FTD and Alzheimer's. They found very different distributions of protein accumulations. The different patterns may serve as a useful tool to differentiate Alzheimer and FTD patients. The researchers hope the technique also can be used to monitor the effectiveness of drugs to clear abnormal proteins such as tau from the brain.
-- MRI Shows Ability to Distinguish Possible Early Alzheimer's and Effects of Treatment
A combination of anatomic and functional magnetic resonance imaging (MRI), which can detect brain abnormalities in people with Alzheimer's disease, may also be able to identify brain changes in people who complain of cognitive deficits but do not meet the criteria for a diagnosis of MCI or Alzheimer's.
Andrew J. Saykin, Psy.D., of Dartmouth Medical School, Lebanon, New Hampshire, leads a team following the progress of 90 older adults as they age. At the outset of the study, 30 of the participants reported no significant declines in memory or other mental functions, while another 30 had cognitive deficits that warranted a diagnosis of MCI. The remaining 30 participants - termed the cognitive complaint group - had perceived deficits in memory and other mental functions that did not reach the threshold for MCI diagnosis and could not be explained by depression or other health problems. The researchers are employing repeat MRI scans to track changes in gray matter and brain activity during memory task performance and comparing the three groups over time. However, even in the baseline study, a surprising parallel was noted between the cognitive complaint and MCI groups.
"The pattern of reduction of gray matter and brain activity in the older adults who complained of cognitive deficits was almost identical to that seen in patients with MCI, suggesting that many of these people may be in the earliest stages of Alzheimer's," said Saykin. "Early detection will be essential as new preventative and treatment strategies become available."
The 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD), presented by the Alzheimer's Association, is the largest gathering of Alzheimer researchers in history. More than 4,500 scientists from around the world will present and discuss the findings of 2,000 studies showcasing the newest treatment advances in Alzheimer's disease and steps toward prevention. ICAD will be held July 17-22, 2004, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.
The Alzheimer's Association is the world leader in Alzheimer research and support. Having awarded more than $165 million to nearly 1,400 projects, the Alzheimer's Association is the largest private funder of Alzheimer research. To sustain the rapid progress, the Association calls for $1 billion in annual federal funding for Alzheimer research. For more information about Alzheimer's disease, visit http://www.alz.org
or call 800-272- 3900.
-- William Klunk - Human Amyloid-Imaging Studies in Controls, Mild Cognitive Impairment and AD Using Pittsburgh Compound B (O3-03-05)
-- Gary Small - In Vivo Imaging of tau Aggregation in Frontal Temporal Dementia Using (F-18)FDDNP Positron Emission Tomography (P2-206)
-- Andrew Saykin - Pre-MCI and MCI Changes on Structural and Functional MRI (IC-P-003)
Contact: Niles Frantz of Alzheimer's Association, 312-286-0295 (cell) or email@example.com
; Alzheimer's Association Media Line, 312-335-4078 or firstname.lastname@example.org
; ICAD press room (July 18-22), 215-418-2054